Biotechnology Sector

A groundbreaking advancement in sustainable water purification has emerged, spotlighting innovative environmental remediation technology that harnesses the potential of biochar derived from microalgal waste. This technology introduces amine-functionalized biochar/cellulose acetate hybrid membranes, specifically engineered to tackle the persistent challenge of municipal wastewater contamination. Researchers have transformed microalgae biomass, an abundant biological residue, into a high-value

In an era where sustainable agriculture and environmental stewardship are paramount, soil health has emerged as a critical focal point for scientists striving to bolster food security and mitigate climate change impacts. Recent advancements in soil amendment research spotlight hydrochar—a carbon-rich material derived from the hydrothermal carbonization of organic waste—as an innovative and remarkably effective

A groundbreaking five-year field experiment has unveiled critical insights into the long-term mitigation of methane emissions from rice paddies—a leading source of agricultural greenhouse gases worldwide. Conducted from 2018 to 2022, the study reveals that not only the presence of biochar, a carbon-rich soil amendment, but the frequency and method of its application profoundly influence

In a groundbreaking study set to reshape our understanding of neuronal repair, researchers have unveiled a novel mechanism by which the aryl hydrocarbon receptor (AhR) modulates axon regeneration through an intricate stress–growth switch. This work, spearheaded by Halawani and colleagues, dives deep into the cellular and molecular dynamics governing nerve injury recovery, revealing insight critical

In a transformative leap forward for cancer therapy, a groundbreaking study published in Cell Death Discovery unveils a unified therapeutic theory that holds the potential to revolutionize how oncologists approach treatment. This pioneering research centers on the universal apoptosis network—a complex biological system governing programmed cell death—and identifies master regulators that could serve as the

In a groundbreaking advancement within the realm of moiré superconductors, recent research has illuminated the intricate evolution of superconductivity in twisted bilayer tungsten diselenide (WSe₂). This work builds upon the expanding family of two-dimensional moiré materials that have captivated the condensed matter physics community, extending well beyond the extensively investigated twisted graphene systems. While prior

The University of Pittsburgh, in collaboration with North Carolina State University, has embarked on a groundbreaking project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy (ARPA-E). This ambitious initiative, known as the Disruptive DC Converters for Grid Resilient Infrastructure to Deliver Secure Energy (DC-GRIDS), aims to dramatically enhance the capacity and reliability

In a significant accolade underscoring the profound impact of emerging technologies, Binghui Wang, an Assistant Professor of Computer Science at Illinois Institute of Technology, has been honored with the 2025 Distinguished Junior Research & Development Award by the Institute of Electrical and Electronics Engineers (IEEE) Chicago Section. This prestigious award, presented annually to an outstanding

In recent years, lung cancer screening programs across the United States have brought to light approximately 1.6 million suspicious lung nodules annually. This surge in detection presents a formidable challenge to pulmonologists and oncologists alike. While the overwhelming majority of peripheral pulmonary lesions identified through screening are benign, it is their malignant counterparts that remain

A groundbreaking study published in npj Parkinson’s Disease has unveiled compelling evidence linking gut microbiota and short-chain fatty acid (SCFA) biomarkers to the early diagnosis of Parkinson’s disease (PD) and the differentiation of its motor subtypes. This pioneering research conducted by Zhang, Du, Gao, and colleagues in 2026 promises to revolutionize the way clinicians detect

In a stride toward the realization of functional quantum networks, a team of researchers from the National Institute of Standards & Technology (NIST) and the University of Colorado, Boulder, has demonstrated the successful transmission of single photons conveying quantum information across kilometers of noisy fiber optic cables. Significantly, the photons retain their quantum coherence and

WASHINGTON, D.C. — In an alarming development for public health, colorectal cancer has surged to become the leading cause of cancer mortality among individuals under the age of 50 in the United States. This emerging crisis has galvanized the Physicians Committee for Responsible Medicine to submit a formal legal petition to the U.S. Department of

In a groundbreaking study emerging from Boston University School of Public Health (BUSPH), researchers have identified a compelling link between financial barriers to dental care and an increased risk of serious health conditions including cardiovascular disease and dementia. This pioneering research, published in The Journals of Gerontology, Series A, delves into how the inability to

In a landmark advancement in cardiology, researchers at Johns Hopkins University have demonstrated the profound clinical potential of “digital twin” technology to improve the treatment of life-threatening arrhythmias. This innovative approach involves creating detailed, personalized digital replicas of a patient’s heart, which can be used to simulate and optimize cardiac procedures before performing them on

As the verdant resurgence of spring graces forests with fresh buds and vibrant hues, scientists are uncovering new visual indicators of tree health that could revolutionize forest ecology monitoring. Dr. Magali Nehemy, a forest hydrology expert at the University of British Columbia Okanagan, has made a compelling discovery: the subtle orientation of tree branches acts

A groundbreaking international meta-analysis has brought to light critical insights regarding the ingestion and bioaccumulation of contaminants of emerging concern (CECs) by agricultural crops, signaling profound implications for environmental and human health alike. These contaminants, encompassing classes such as pharmaceuticals, microplastics, engineered nanomaterials, and per- and polyfluoroalkyl substances (PFAS)—often dubbed “forever chemicals” due to their

In a landmark advancement for the treatment of stage III colon cancer characterized by deficient DNA mismatch repair (dMMR), researchers at the VCU Massey Comprehensive Cancer Center have played a pivotal role in defining a new therapeutic standard through the results of an international phase III clinical trial. This study, which stands at the forefront

A revolutionary breakthrough in the treatment of severe sickle cell disease (SCD) has been reported from the latest data emerging from the multicenter RUBY Trial, producing highly promising outcomes that could redefine therapeutic strategies for this challenging genetic blood disorder. The findings, published in the prestigious New England Journal of Medicine, demonstrate unprecedented clinical success

A groundbreaking innovation in the fight against melanoma, one of the most aggressive and fatal skin cancers, has emerged from recent research published in ACS Nano. Scientists have engineered a novel, noninvasive treatment modality in the form of a stretchable, heat-activated skin patch that promises to revolutionize melanoma therapy by potentially eliminating the need for

In a groundbreaking new study spearheaded by researchers at Adelaide University and the University of Canberra, critical evidence has emerged linking exposure to extreme heat with an increased incidence of low birth weight in newborns. Published recently in the peer-reviewed journal BMC Medicine, this collaborative research employs an extensive dataset comprising over 85,000 mother-infant pairs

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials.

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the Pfizer-partner Lyme disease vaccine, VLA15, is very much “a matter of negotiation.”

After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while outlining a claimed edge over Pfizer’s rival candidate.

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures.

Half a year after being spurned by the FDA and following several rounds of deep layoffs, IO Biotech has decided to close its doors for good.

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals and its sleep disorder pipeline.

A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its existing drug.

Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of the road, with the biotech filing for bankruptcy.

The New Jersey pharma is tapping Infinimmune to hunt for antibodies for as-of-yet undisclosed targets.

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.

Autoimmune specialist Aurinia, which named Kevin Tang as its new CEO last week, is acquiring Kezar after the latter company received promising feedback from the FDA. Tang previously made an unsuccessful attempt in 2024 to acquire Kezar via Concentra Biosciences and its parent company, Tang Capital Partners.

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune disease treatment, with Royalty pitching in $500 million over the next two years.

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.

Despite the primary endpoint hit, the candidate's inability to meet investors’ expectations cast a shadow over the results.

Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure.

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the autoimmune disease.

Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.

KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched $1.3 billion deal and fraud allegations, Fierce Biotech has learned.

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.

Radioligand therapy has irrevocably changed oncology, proving we can map biology and strike cancer cells with unprecedented precision. Research suggests that up to 80% of cancers could potentially be addressed by this approach.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...